Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides

Pierre Charles; Boris Bienvenu; Bernard Bonnotte; Pierre Gobert; Pascal Godmer; Eric Hachulla; Mohamed Hamidou; Jean-Robert Harle; Alexandre Karras; Jean-Christophe Lega; Alain Le Quellec; Alfred D. Mahr; Luc Mouthon; Thomas Papo; Xavier Puechal; Gregory Pugnet; Maxime Samson; Jean Sibilia; Benjamin Terrier; Frederick Vandergheynst; Loic Guillevin; FVSG

doi:10.1016/j.lpm.2013.08.003

Retour

Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides

Article de revue scientifique

Avec comité de lecture

Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides

Pierre Charles, Boris Bienvenu, Bernard Bonnotte, Pierre Gobert, Pascal Godmer, Eric Hachulla, Mohamed Hamidou, Jean-Robert Harle, Alexandre Karras, Jean-Christophe Lega, …

La Presse médicale (1983), Vol.42(10), p.1317-1330

01/10/2013

DOI: https://doi.org/10.1016/j.lpm.2013.08.003

PMID: 24095054

Résumé

General & Internal Medicine

Life Sciences & Biomedicine

Medicine, General & Internal

Science & Technology

Increasing rituximab prescription for ANCA-associated necrotizing vasculitides justifies the publication of recommendations for clinicians. Rituximab is approved in the United States to induce and maintain remission. In Europe, rituximab was recently approved for remission induction. However, governmental agencies' approvals cannot replace clinical practice guidelines. Herein, the French Vasculitis Study Group Recommendations Committee, comprised of physicians with extensive experience in the treatment of vasculitides, presents its consensus guidelines based on literature analysis, the results of prospective therapeutic trials and personal experience.

Indicateurs

1 Consultations de la notice

Détails

Titre: Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides
Créateurs - sans rôle: Pierre Charles - Univ Paris 05, Cochin Hosp, AP HP, Dept Internal Med, F-75014 Paris, France
Boris Bienvenu - CHU Cote Nacre, F-14033 Caen, France
Bernard Bonnotte - Univ Hosp Dijon, Dept Internal Med & Clin Immunol, F-21079 Dijon, France
Pierre Gobert - Ctr Hosp Avignon, Dept Internal Med & Nephrol, F-84902 Avignon, France
Pascal Godmer - Ctr Hosp Bretagne Atlantique, F-56000 Vannes, France
Eric Hachulla - Université de Lille
Mohamed Hamidou - Nantes Université
Jean-Robert Harle - La Concept Hosp, Dept Internal Med, F-13385 Marseille, France
Alexandre Karras - Univ Paris 05, Georges Pompidou Hosp, AP HP, Dept Nephrol, F-75015 Paris, France
Jean-Christophe Lega - Univ Lyon 1, Ctr Hosp Lyon Sud, Hosp Civils Lyon, Dept Internal Med & Vasc Med, F-69500 Lyon, France
Alain Le Quellec - Ctr Hosp Reg Univ St Eloi, Dept Internal Med, F-34295 Montpellier 5, France
Alfred D. Mahr - Univ Paris Diderot, St Louis Hosp, AP HP, Dept Internal Med, F-75010 Paris, France
Luc Mouthon - Univ Paris 05, Cochin Hosp, AP HP, Dept Internal Med, F-75014 Paris, France
Thomas Papo - Univ Paris Diderot, Bichat Hosp, AP HP, Dept Internal Med, F-75018 Paris, France
Xavier Puechal - Univ Paris 05, Cochin Hosp, AP HP, Dept Internal Med, F-75014 Paris, France
Gregory Pugnet - Univ Hosp Toulouse, Dept Internal Med, F-31059 Toulouse, France
Maxime Samson - Univ Hosp Dijon, Dept Internal Med & Clin Immunol, F-21079 Dijon, France
Jean Sibilia - Univ Hosp Strasbourg, Dept Rheumatol, F-67098 Strasbourg, France
Benjamin Terrier - Univ Paris 05, Cochin Hosp, AP HP, Dept Internal Med, F-75014 Paris, France
Frederick Vandergheynst - Free Univ Brussels, Erasme Hosp, Dept Internal Med, B-1050 Brussels, Belgium
Loic Guillevin - Univ Paris 05, Cochin Hosp, AP HP, Dept Internal Med, F-75014 Paris, France
FVSG
Détails de publication: La Presse médicale (1983), Vol.42(10), p.1317-1330
Éditeur: Elsevier
Nombre de pages: 14
Note de subvention: Pfizer Novartis Octapharma LFB Actelion Roche Laboratory; Roche Holding CSL Behring Merck Sharp; Merck & Company InterMune Amgen
Identifiants: 99234074709311
Unité académique: IRMB - Cellules souches, plasticité cellulaire, régénération tissulaire et immunothérapie des maladies inflammatoires
Langue: Anglais
Type de ressource: Article de revue scientifique